Sunday, November 15, 2026

Psychotropic Trials on Consumers of Behavioral Health Services by Keith Torkelson MS, BS VTorkel

  


Contents

  • Requirements and Specifications
  • Results Up Front
  • Results Up Front – Master Medications List
  • When a doctor tries you on a new medication is it an experiment?
  • Experimentation on Human Subjects
  • Clozapine Algorithm
  • Fleshing Issues by Medication
  • E.H.R. Experiment – Increase in Error Rate (Circa 2026)
  • Chemically validated diagnoses for mental illness
  • Typical Antipsychotics
  • Atypical Antipsychotics
  • More - How is it that Risperadone and Invega were ineffective for me?
  • Fleshing Issues by People (MDs & NPs)
  • Brain Games – Reversing or Slowing the Effects of Dementia
  • Integrated Circuits to Treat Mental Illness
  • Therapeutic changes in brain circuitry and chemistry
  • Evolution of ECT
  • What is a Chemical Lobotomy?






Results Up Front – Master Medications List – Part I of II

Not in Chronological Order




Master Medications List – Part II of II

Not in Chronological Order




When a doctor tries you on a new medication is it an experiment?

No, giving you a new medication is generally not an experiment.

Why It Is Not an Experiment

Extensive Testing First:

Before a medication is approved by agencies like the U.S. Food and Drug Administration (FDA), it undergoes years of laboratory research and Clinical Trials (Phase I–III) involving thousands of patients to prove it is safe and effective.

Tailored Treatment:

When your doctor prescribes a new medication, they rely on clinical guidelines, medical training, and your specific health history to find the best option for your condition—not to test an unknown theory on you.

Individual Response:

Every person's body reacts differently to pharmaceuticals. Adjusting a dose or switching to a different drug is a process of individualized fine-tuning, rather than scientific experimentation.

When Medication Is Experimental

A medication is considered experimental only under specific circumstances:

Clinical Trials:

You are explicitly enrolled in a structured Clinical Trials Research Study designed to answer a scientific research question.

Investigational Drugs:

You are taking a drug that has not yet received regulatory approval and is still being tested for safety or efficacy, often accessed through specialized trials or expanded access programs.

Off-Label Use:

A doctor prescribes an already-approved drug for a condition or age group it wasn't originally studied for. While common and legal, this relies on clinical experience rather than primary trial data for that specific use.

 

Experimentation on Human Subjects

Experiments on human subjects involve systematic scientific investigations—either interventional or observational—designed to collect data for medical or social science research.

Core Ethical Principles

Modern human subject research is guided by strict legal and ethical frameworks to prevent abuse and protect participants:

Voluntary Informed Consent:

Subjects must fully understand the nature, risks, and benefits of a study and agree to participate of their own free will.

Right to Withdraw:

Participants can leave a study at any time without facing penalties or loss of benefits.

Protection from Harm:

Researchers must minimize physical, psychological, or social risks.

Institutional Oversight:

Most regulated research requires approval from an Institutional Review Board (IRB) or ethics committee before it can begin.

Key Historical Milestones

Global and national guidelines were shaped largely in response to historical violations:

Nuremberg Code (1947):

Formulated after World War II in response to Nazi medical atrocities; established the absolute necessity of voluntary consent.

Declaration of Helsinki (1964):

Developed by the World Medical Association as a cornerstone guide for ethical medical research involving human subjects.

Belmont Report (1978) & Common Rule (1991):

Set the foundation for ethical research regulations in the United States, emphasizing respect for persons, beneficence, and justice.

Notable Examples of Unethical Experiments

History includes many instances where ethical principles were severely violated, often targeting prisoners, soldiers, or marginalized populations without consent:

Nazi Human Experimentation & Unit 731:

Brutal medical torture, hypothermia studies, and biological warfare tests conducted during World War II.

Tuskegee Syphilis Study:

A multi-decade U.S. Public Health Service study that withheld treatment from Black men with syphilis without their informed consent.

Project MKUltra:

Clandestine U.S. CIA experiments involving mind-altering substances like LSD and psychological interrogation techniques.

Psychological Studies:

Famous social experiments like the Stanford Prison Experiment and the Milgram obedience experiments raised serious questions about psychological harm and participant distress.


Clozapine Algorithm

We should have been tried on CloZAPine after 3-4 failures on anti-psychotics

We were a candidate in the early 1990s yet did not get on it until 2006



Fleshing Issues by Medication

Common issues and side effects caused by medicines fall into several main categories, ranging from routine reactions to severe medical risks.

Common Physical and Digestive Side Effects

Digestive discomfort:

Nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and iron supplements can cause nausea, diarrhea, constipation, gastritis, or stomach ulcers.

Esophageal irritation:

Pills like aspirin, doxycycline, or vitamin C can stick in the throat and cause local ulcers or bleeding if swallowed without enough water.

Drowsiness and dizziness:

Antihistamines, antidepressants, blood pressure medications, and sleep aids frequently cause fatigue, brain fog, or lightheadedness.

Balance and fall risks:

Polypharmacy (taking multiple drugs at once) and high-risk medications like sedatives or muscle relaxants increase the chance of falls, especially in older adults.

Drug Interactions

Pharmacokinetic changes:

One drug can alter how another is processed by the liver or kidneys (for example, grapefruit juice interacts with statins to raise drug levels in the blood).

Additive or dangerous effects:

Combining blood thinners with NSAIDs escalates bleeding risks, while mixing St. John's wort or herbal supplements with antidepressants can trigger life-threatening serotonin toxicity.

Severe Allergic and Systemic Reactions

Severe skin and immune reactions:

Rare but life-threatening responses include Anaphylaxis, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS reaction.

Symptom masking:

Using over-the-counter or temporary symptom-relief drugs without identifying the root cause can allow underlying diseases to progress dangerously.

Supply Chain and Manufacturing Issues

Generic drug quality and shortages:

A large portion of generic drug manufacturing occurs overseas, leading to occasional oversight challenges, contamination risks, and shortages of vital treatments in the United States.


E.H.R. Experiment – Increase in Error Rate (Circa 2026)

Studies show that Electronic Health Record (EHR) error rates vary widely—ranging from 15% to over 50% depending on task complexity, vendor design, and workflow delays.

Key Findings on EHR Error Rates

Operating Room Documentation:

A recent PMC study found an overall documentation error rate of 17.01%, surging from 1.30% with no delay to 38.43% for documentation delays exceeding 20 minutes 0.6.1.

Medication Errors:

Research from University of Utah Health revealed that EHR systems fail to detect up to 33% (one in three) of potentially harmful medication errors and drug interactions.

Task Variability:

A JAMIA study tracking emergency medicine ordering scenarios across Epic and Cerner systems found error rates reaching up to 50%, with an eightfold difference in required mouse clicks.

Patient-Reported Mistakes:

In a JAMA Network Open study, 1 in 5 patients who read their visit notes reported finding a mistake, with 40% perceiving the error as serious.

Main Causes of Increased Error Rates

Documentation Delays:

Rushing to catch up on delayed charting drastically spikes mistakes during high-intensity procedures.

Information Overload & Alert Fatigue:

Excessive notifications, poor interface design, and "note bloat" increase cognitive burden on clinicians.

Local Customization:

Hospitals often modify software and disable decision-support alerts independently, while federal regulations typically inspect only baseline factory software.

Copy-Paste Culture:

Reusing old text propagates outdated or inaccurate clinical information across charts.


Chemically validated diagnoses for mental illness

There are no chemically validated (biomarker-based) diagnostic tests used to confirm mental illnesses.

Clinical Assessment Only:

Psychiatric diagnoses—such as Major Depressive Disorder, Schizophrenia, Bipolar Disorder, or Anxiety—are made through clinical interviews, mental state evaluations, and standardized criteria like the DSM-5 rather than blood, urine, or brain-chemistry assays.

Excluding Physical Causes:

Lab tests (such as blood or thyroid panels, drug screens, or imaging) are ordered strictly to rule out non-psychiatric medical issues (like nutritional deficiencies, neurological tumors, or autoimmune conditions such as lupus) that can mimic psychiatric symptoms.

The "Chemical Imbalance" Myth:

The popular idea that mental health disorders are diagnosed or caused by a simple, measurable chemical imbalance in the brain is an oversimplification. While neurotransmitters, inflammation markers, and metabolomics are active areas of research, psychiatry currently relies on a bio-psycho-social model rather than objective chemical tests.



(*) Absolutely miserable medications.  Complicated anxiety and sleep issues.  Severe adverse reactions including Tardive Dyskinesia and Muscle Rigidity.



Other Medications

Risperadone (Risperdal) was ineffective for us.  Invega monthly injection was ineffective for us on two different occasions.  It makes sense that Invega would not be effective. Invega itself is not a metabolite; Invega (brand name for paliperidone) is already the active form and is the major active metabolite of the older antipsychotic medication risperidone (Risperdal).

 

More - How is it that Risperadone and Invega were ineffective for me?

Risperidone and Invega (paliperidone) are chemically almost identical, meaning that if one does not work for your body, the other is also very likely to be ineffective. When your body processes risperidone, it breaks it down into paliperidone, which is the exact active ingredient in Invega. Because both drugs act on the exact same brain pathways, they share the same core mechanism. Several biological and clinical factors can explain why neither medication worked for you.

Shared Pharmacology

The Active Metabolite Link.

Paliperidone is the primary active metabolite of risperidone. Taking Invega essentially skips the liver processing step required by risperidone, delivering the same active compound directly to your system.

Identical Receptor Targets.

Both medications work primarily by blocking specific dopamine (D2) and serotonin (5-HT2A) receptors in the brain. If your specific symptoms are not driven by this exact receptor pathway, neither medication will provide relief.

Individual & Clinical Factors

Genetic Variations in Brain Receptors.

Every person has unique variations in their dopamine and serotonin receptors. Your specific receptor makeup may simply not respond well to how these two drugs bind to them.

Diagnosis and Symptom Mismatch.

While both medications treat conditions like schizophrenia, they do not target every symptom type equally. For instance, they are generally less effective for depressive episodes or negative symptoms like low motivation and emotional blunting.

Duration Limits.

Antipsychotic medications often take several weeks to show their full effect. If treatment was stopped early or adjusted before reaching a stable regimen, the medication may not have had an adequate period to work.

Treatment Resistance.

Some individuals have conditions that do not respond to standard first-line dopamine blockers. In these cases, a completely different class of medication—such as cloZAPine or newer agents that target different brain chemicals—is often needed.

What to Discuss With Your Prescriber

Trying a Different Chemical Class.

Since both of these drugs rely on the same compound, ask your doctor about switching to an antipsychotic with a different chemical structure and receptor profile.

Reviewing Your Trial History.

Share the details of your previous regimens and how long you took each medication so your doctor can evaluate if you completed a full clinical trial.


Fleshing Issues by People (MDs & NPs)

Scored by and for Keith “Buster” Torkelson, MS, BS




These values have been updated since publishing a report card in previous studies.

(*) Dr. Dobos had bi-weekly medication management groups which was the most efficient manner to handle a caseload that we ever experienced.  Unfortunately we went to the hospital on his watch.

(**) These scores will vary between papers and are subject to change.

 

Brain Games – Reversing or Slowing the Effects of Dementia

Brain games and cognitive exercises target specific mental skills like memory, attention, problem-solving, and speed.

 

Popular Online Platforms & Apps

 

Lumosity:

Features over 40 research-inspired games targeting memory, speed, attention, flexibility, and problem-solving.

Games for the Brain:

Offers classic browser-based logic and puzzle games like Sudoku, Chess, Checkers, Reversi, and Mahjongg.

Mind Games:

Provides a free catalog of daily word searches, nonograms, Sudoku, crosswords, and memory games.

Wordle & Variations:

Daily word puzzles like the official NYT Wordle or community-favored variations (Quordle, Octordle) help with vocabulary and pattern recognition.

 

Classic & Real-World Brain Games

 

Number Puzzles:

Sudoku and number sums build logical thinking and concentration.

Word & Language Games:

Crosswords, Scrabble, Boggle, and Taboo strengthen verbal fluency and crystallized intelligence.

Strategy & Board Games:

Chess, Checkers, Bridge, Uno, and Monopoly challenge executive function, working memory, and real-time problem-solving.

Visuospatial Puzzles:

Jigsaw puzzles, find-the-difference sheets, and mazes help protect visuospatial functioning as you age.


Integrated Circuits to Treat Mental Illness

Modern psychiatry increasingly views mental illness—such as treatment-resistant depression and obsessive-compulsive disorder (OCD)—not merely as a chemical imbalance, but as a disorder of brain circuits. Integrated circuits, microchips, and implantable electronic devices are at the forefront of a shift toward precision neuromodulation.

How Integrated Circuits and Implants Work in Psychiatry

Deep Brain Stimulation (DBS):

Involves surgically implanting miniature electrodes or pacemaker-like devices directly into specific brain regions (such as the subgenual anterior cingulate cortex). These integrated systems deliver controlled electrical pulses to modulate and "rewire" dysfunctional neural networks.

Closed-Loop Systems:

Newer implantable and wearable technologies are designed to monitor real-time brain activity and deliver stimulation only when specific biomarker patterns or abnormal circuit activity are detected.

Targeting Resistant Conditions:

These hardware approaches are primarily studied and deployed for patients with severe, treatment-resistant major depressive disorder (TRD) or debilitating OCD who have not responded to psychotherapy or multiple medications.

Non-Invasive Alternative Circuit Therapies

For patients who do not require or want surgical implants, circuit-level modulation is also achieved via non-invasive tools:

Transcranial Magnetic Stimulation (TMS):

Uses external electromagnetic coils placed on the scalp to stimulate mood-regulating brain regions like the dorsolateral prefrontal cortex without anesthesia or surgery.

Electroconvulsive Therapy (ECT):

A well-established clinical therapy that uses regulated electrical currents under anesthesia to induce therapeutic changes in brain circuitry and chemistry for severe episodes.

 


Therapeutic changes in brain circuitry and chemistry

Therapeutic interventions—including psychotherapy, pharmacotherapy, and neuromodulation—induce measurable structural and chemical adaptations in the brain through neuroplasticity.

Changes in Brain Circuitry (Structure & Activity)

Prefrontal Cortex (PFC):

Talk therapy and cognitive behavioral approaches strengthen top-down emotional regulation by increasing functional activity and gray matter volume in executive control regions.

Amygdala and Limbic System:

Overactive alarm centers that drive fear, anxiety, and hyper-reactivity show reduced baseline volume and decreased hyper-reactivity following successful treatment.

Synaptic Remodeling:

Interventions promote the growth of new dendritic spines and prune outdated or stress-induced connections, allowing neural circuits to reorganize.

Targeted Circuit Stimulation:

Advanced approaches like Vagus Nerve Stimulation or deep-brain stimulation directly target specific white-matter pathways (such as the subcallosal cingulate) to reset malfunctioning loops in treatment-resistant conditions.

Changes in Brain Chemistry (Neurotransmitters & HPA Axis)

Serotonin and Dopamine:

Therapeutic modalities elevate availability and receptor sensitivity for key mood-stabilizing and reward-regulating neurotransmitters.

GABA and Glutamate:

Treatments enhance inhibitory neurotransmission via GABA while dialing down excessive excitatory glutamate and norepinephrine signaling.

BDNF (Brain-Derived Neurotrophic Factor):

Therapy and lifestyle interventions trigger BDNF release, which supports the survival of existing neurons and encourages the growth of new synapses.

Stress Hormone Regulation:

Modulating the hypothalamic-pituitary-adrenal (HPA) axis lowers chronic cortisol output, protecting the hippocampus from stress-induced volume loss.

 

Would you like to explore how a specific intervention (such as Cognitive Behavioral Therapy, antidepressants, or mindfulness) affects a particular mental health condition?

 
Evolution of ECT

Electroconvulsive therapy (ECT) has evolved from a crude, unanesthetized chemical and electrical intervention into a highly regulated, safe, and precise neuromodulation procedure.

Key Stages of Evolution

Pre-ECT Chemical Convulsive Era (1930s): The practice grew out of early theories that induced seizures could alter mental illness. Ladislas J. Meduna used intramuscular camphor and later Metrazol (cardiazol) to chemically induce seizures in patients with schizophrenia, though it caused severe pre-seizure panic and high physical risk.

Invention of Electrical ECT (1938): Italian psychiatrists Ugo Cerletti and Lucio Bini replaced chemical agents with controlled electrical currents delivered to the scalp, performing the first human ECT treatment in Rome.

The "Unmodified" Era (1938–1950s):

Early ECT was administered "unmodified"—meaning without anesthesia or muscle relaxants. High-voltage alternating currents (AC) induced violent motor convulsions that occasionally led to bone fractures, dental injuries, and severe post-procedure confusion.

Introduction of Anesthesia and Muscle Relaxants (1940s–1952):

Wladimir T. Liberson (1944) shortened stimulus durations, reducing cognitive blunting.

General anesthesia and barbiturates were introduced for patient comfort.

Paralytic muscle relaxants—initially curare and later replaced by succinylcholine (1952)—eliminated violent physical muscle contractions while preserving the therapeutic brain seizure ("modified ECT").

Refinement of Electrical Waveforms and Placement (1970s–Present):

Brief-pulse and ultrabrief-pulse stimuli replaced traditional sine waves, drastically cutting down memory impairment and cognitive side effects.

Unilateral ECT (applying electrodes to only one hemisphere) was adopted alongside traditional bilateral placement to further protect memory function.

Modern Status:

Today, ECT is recognized as a vital, fast-acting treatment for severe, treatment-resistant depression, acute mania, catatonia, and psychotic depression, backed by safety standards and continuous innovations like magnetic seizure therapy.

 


What is a Chemical Lobotomy?

A chemical lobotomy is a non-medical, descriptive term used to describe the heavy sedation and emotional flattening caused by certain powerful psychiatric or sedative medications—most historically antipsychotics like chlorpromazine (Thorazine).

Origins and History

The Rise of Antipsychotics:

In the early 1950s, the introduction of early antipsychotic drugs like chlorpromazine revolutionized psychiatric care. Because these drugs rapidly calmed, quieted, and sedated agitated or psychotic patients without physical surgery, observers and historians dubbed them a "chemical lobotomy".

Replacing Physical Surgery:

Before these medications became widespread, severe mental health conditions were sometimes treated with physical psychosurgery (such as standard or transorbital lobotomies) or harsh shocks. Drugs offered a non-surgical, more predictable way to manage symptoms, though they carried their own intense sedative and neurological side effects.

Common Meanings and Contexts

Historical/Medical Metaphor:

Originally applied to the first generation of major tranquilizers and antipsychotics that suppressed acute mania, hallucinations, or severe agitation.

Critiques of Long-Term Medication:

In modern discussions, critics, patients, or advocacy groups sometimes use the term colloquially to describe the side effects of prolonged or high-dose psychiatric medications (such as antipsychotics, mood stabilizers, or heavy painkillers). These effects can include:

  • Emotional numbing or apathy
  • Cognitive dullness or brain fog
  • Chronic fatigue and physical sluggishness
  • Involuntary movements or tremors




Wednesday, November 11, 2026

Global Appraisal of Needs (GAIN) by Keith Torkelson MS, BS

 

Contents

Requirements/Specifications

Promotions – Residential Treatment

Rigorous – GAIN Model - Indexing Notion Source

Young Person in Recovery (YPR)

Global Appraisal of Individual Needs (GAIN) overview

GAIN

FYI – GAIN Indexing – Lost Information

Aside - Geoff Henderson – Person of Interest (SUD)

Real Time GAIN Score from 2025

Retroactive GAIN Score from 1971 (Age 12)

Ways the sobriety is an easier life style than a substance user

Residential Treatment for Substance Use Disorder

Impact of Substance Use Disorder

If you get a DUI do you have Substance Use Disorder?

DSM-5 criteria for substance use disorder

Why and when is substance use disorder hopeless?

 

Promotions – Residential Treatment

A Better Tomorrow

A Better Today

Hope by the Sea

Anaheim Lighthouse



Rigorous – GAIN Model - Indexing Notion Source

Years ago, Buster was invited to serve and advise on the Orange County Health Care Agency’s (OCHCA’s) Technological Needs Committee (TAC).  Geoff Henderson of Phoenix House (Substance Use Disorder service) made a showing early on before he decided not to participate.  In one meeting, Geoff mentioned an assessment tool (system) that Phoenix House was using with its’ consumers.  The system is called Global Appraisal of Individual Needs, or GAIN.  Obviously, if Buster had free access to the GAIN software, he would run a GAIN on himself.  If and when we here at Mentalation Solutions Group (MSG) run a GAIN for Buster it will take substantial modification.  Many of the GAIN scales could be helpful in Buster’s case.

 

Associated with
Young Person in Recovery (YPR)
06_Workbook_Phoenix_YPR_Recovery_23120104_Tracking V2026
https://healthman2059.blogspot.com/2026/08/young-people-keeping-it-right-by-keith.html

 

Global Appraisal of Individual Needs (GAIN) overview

Development and purpose

The Global Appraisal of Individual Needs (GAIN) originated in 1993 as a collaboration between clinicians, researchers, and policymakers from over a dozen behavioral healthcare agencies to create a comprehensive biopsychosocial assessment tool. It is a progressive and integrated series of measures and computer applications designed to support a number of treatment practices, including initial screenings; brief interventions; referrals; standardized clinical assessments for diagnosis, placement, and treatment planning; monitoring of changes in clinical status, service utilization, and costs to society; and subgroup- and program-level needs assessment and evaluation.

 

Lost Resource > In House Metadata >



Tangent - GAINs

The Global Appraisal of Individual Needs (GAIN) is a standardized, evidence-based biopsychosocial assessment tool developed in 1993 by Dr. Michael Dennis and the Lighthouse Institute at Chestnut Health Systems. It is widely used to evaluate substance use, mental health, physical health, crime and violence, and environmental factors in clinical, correctional, and social service settings.

You can explore the full range of resources via the GAIN Coordinating Center or check program instruments through Chestnut Health Systems.

Core Components of the GAIN Family

The GAIN is structured as an integrated family of instruments scaled for different phases of care:

GAIN Short Screener (GAIN-SS):

A quick 3- to 5-minute screener used to identify or rule out behavioral health issues. It covers four main subscales: Internalizing Disorders (depression, anxiety, suicide), Externalizing Disorders (ADHD, impulsivity, conduct problems), Substance Use Disorders, and Crime and Violence. Scores range from low (0), moderate (1–2), to high (3+), indicating whether a full assessment is needed.

GAIN Initial (GAIN-I):

A comprehensive, in-depth clinical and research assessment used for diagnosis, placement, and treatment planning. It maps responses directly to criteria in the DSM-5 and the ASAM (American Society of Addiction Medicine) Criteria.

GAIN-Q3 / GAIN-Q4:

Shorter assessment and quick-intake tools designed for brief interventions, service referrals, and level-of-care determinations.

GAIN Monitoring 90 Days (GAIN-M90):

A quarterly follow-up instrument used to track changes in a client's clinical status, service utilization, and societal costs over time.

Key Assessment Domains

Across its instruments, the GAIN evaluates multiple life areas:

Substance use, frequency, withdrawal, and readiness to change

Mental health (internalizing and externalizing symptoms)

Physical health, infectious disease risks (HIV, Hepatitis, TB), and medical history

Crime, violence, and rule-breaking behavior

Vocation, education, and quality of life

Environmental stress and general service utilization


FYI – GAIN Indexing – Lost Information



Matrix – Model for Intensity – Last Applied: 20180131-W:  Original Lead: Phoenix House - Geoff Henderson phoenix house (Circa 2009).  20210727-TU we just found out a couple of weeks ago that Geoff is retiring.  We took the time to discover Geoff’s digital legacy.




Aside - Geoff Henderson – Person of Interest (SUD)




Human Services Professional - SUD, MH, Corrections, Trainer, Consultant, Teacher

Chandler, Arizona, United States

About

Experienced Leader in Behavioral Health, Substance Use Treatment, Criminal Justice Reentry and Education.

With 30+ years of leadership experience spanning behavioral health, substance use disorders, corrections, and human services, I specialize in designing and delivering innovative, evidence-based programs across diverse systems of care and teaching.  Most recently served as Sr. Consultant at AHP, where I recently led a statewide network of Medication-Assisted Treatment (MAT) programs across California; Technical Consultant to the CA statewide treatment program expansion effort- Behavioral Health Continuum Improvement Project (BHCIP) and facilitating targeted technical assistance/training to counties and organizations across the country.. My focus is to build high-impact services at the intersection of behavioral health and criminal justice.

Previous highlighted roles include:

Administrative Manager II, OC Sheriff's Department

Inmate Programs & Services Manager- Oversaw all in-custody treatment, education, and reentry services across county jails.

Vice President, Phoenix House California

Directed and developed a statewide portfolio of programs, both youth and adult, including residential/outpatient treatment, wraparound services, jail-based and prison addiction treatment, sober housing, and recovery maintenance; including new business development & marketing

Regional Administrator, Telecare Corp

Managed behavioral health programs in Ventura County, including ACT, residential, prevention/early intervention, and reentry services for justice-involved populations.

Nationally trained in the Transitions from Jail to Community (TJC) model by the National Institute of Corrections and an active leader in local reentry reform efforts. I've held leadership roles with the OC Re-Entry Partnership (Chair), LA Reentry Partnership, and Ventura Reentry Coalition.

Academic Roles:

College instructor at Saddleback College and Riverside City College, where I helped launch the Human Services Occupational Certificate Program. Field Supervisor for Special Education teacher interns at CSU Fullerton. Frequent guest lecturer and conference presenter.

 

Core Strengths:

✔️ Criminal Justice Reentry
✔️ Co-Occurring Disorder Treatment
✔️ Program Development & Expansion
✔️ Appreciative Inquiry & Change Leadership
✔️ Digital Integration in Behavioral Health
✔️ Functional Applied Behavioral Analysis


Real Time GAIN Score from 2025
The system is called Global Appraisal of Individual Needs or GAIN.
Order Retained - SUD and Its Impact
[R] = Reverse Scoring | GAIN = Global Appraisal of Individual Needs | LSF = Low Scores are Favorable | RT = Real Time | SWJB = Share with John Baer
Score by and for Buster on 20250324-M-RT-SW-JB

##

Scale Index

 

2025
0324
M-RT
KET
QSM
SW-JB

01

Substance Problem Scale (Lifetime)

1.00

02

Substance Frequency Scale

0.00

03

Current (Past Week) Withdrawal Scale

0.00

04

Health Distress Scale

0.50

05

Health Problem Scale

0.50

06

Cognitive Impairment Scale Summative

0.50

07

Internal Mental Distress Scale

0.50

08

Traumatic Stress Scale

0.50

09

Behavior Complexity Scale

1.00

10

Emotional Problem Scale

0.50

11

Treatment Resistance Index Summative

0.25

12

Treatment Motivation Index Summative [R]

0.00

13

Self-Efficacy Scale [R]

0.25

14

Problem Orientation Scale Summative

0.50

15

Environmental Risk Index

0.75

16

Recovery Environment Risk Index Summative

0.50

17

General Conflict Tactic (Violence) Scale

0.00

18

General Victimization Scale

0.33

19

Personal Sources of Stress Index Summative

0.50

20

Other Sources of Stress Index Summative

0.50

21

General Social Support Index Summative [R]

0.50

22

Illegal Activities Scale

0.00

23

Employment Activity Scale [R]

0.25

24

Training (School) Activity Scale [R]

0.00

 

CALC

=9.33/24

 

GAIN Index Score (LSF) =

38.9%

 

The system is called Global Appraisal of Individual Needs or GAIN.

Retroactive GAIN Score from 1971
Order Retained - SUD and Its Impact
[R] = Reverse Scoring | GAIN = Global Appraisal of Individual Needs | LSF = Low Scores are Favorable | RT = Real Time | SW = Solo
Score by and for Buster on 20260807-F-Retro-SW-Solo
 

##

Scale Index

 

1971
Scored
QSM
SW-Solo

01

Substance Problem Scale (Lifetime)

0.25

02

Substance Frequency Scale

0.25

03

Current (Past Week) Withdrawal Scale

0.00

04

Health Distress Scale

0.00

05

Health Problem Scale

0.25

06

Cognitive Impairment Scale Summative

0.00

07

Internal Mental Distress Scale

0.25

08

Traumatic Stress Scale

0.25

09

Behavior Complexity Scale

0.25

10

Emotional Problem Scale

0.25

11

Treatment Resistance Index Summative

0.25

12

Treatment No Motivation Index Summative

0.25

13

No Self-Efficacy Scale

0.00

14

Problem Orientation Scale Summative

0.25

15

Environmental Risk Index

1.00

16

Recovery Environment Risk Index Summative

1.00

17

General Conflict Tactic (Violence) Scale

0.25

18

General Victimization Scale

1.00

19

Personal Sources of Stress Index Summative

0.50

20

Other Sources of Stress Index Summative

0.25

21

General No Social Support Index Summative

0.75

22

Illegal Activities Scale

0.25

23

Employment No Activity Scale

0.00

24

Training (School) No Activity Scale

0.00

 

CALC

=7.50/24

 

GAIN Index Score (LSF) =

31.3%

 

Ways the sobriety is an easier life style than a substance user

Sobriety offers a fundamentally simpler and less chaotic daily existence compared to active substance use, removing the constant mental, physical, and financial drain of chasing or recovering from intoxication.

Key Ways Sobriety is Easier

Mental Clarity and Decision-Making:

Without a substance dictating your impulses or clouding your judgment, you make conscious, rational choices rather than reacting out of craving, withdrawal, or intoxication.

Elimination of Hangovers and Physical Recovery:

Sobriety spares your body the daily exhaustion of hangovers, nausea, brain fog, dehydration, and long-term organ strain, replacing them with steady natural energy and deep REM sleep.

Financial Stability:

Sustaining a substance habit is expensive. Sobriety stops the continuous cycle of spending money on drugs or alcohol and the collateral costs of legal issues, medical bills, or lost productivity.

Reclaimed Time:

Active substance use acts like a full-time job—securing the substance, using it, and recovering from it. Sobriety gives you hours back each day to invest in hobbies, work, and personal goals.

Simpler Relationships:

Hiding habits, managing conflicts caused by erratic behavior, and apologizing for past mistakes create immense social friction. Sobriety brings emotional consistency, trust, and authentic presence to relationships.

Peace of Mind:

You no longer have to spend energy running from guilt, covering up tracks, or worrying about what you said or did while impaired.

Resources like the Recovery Centers of America Guide and Alcohol Help break down how trading a cycle of consumption for steady habits lightens your daily load.


Residential Treatment for Substance Use Disorder

Residential treatment is a structured, live-in model of care where individuals reside full-time at a non-hospital facility while receiving intensive mental health, behavioral, or substance use treatment.

Key Characteristics

24/7 Care and Supervision:

Residents receive round-the-clock monitoring and support in a structured, safe environment.

Non-Hospital Setting:

Unlike acute hospital-based inpatient care—which focuses on short-term crisis stabilization—residential treatment offers a more home-like, therapeutic atmosphere for longer-term healing.

Comprehensive Therapies:

Programs typically combine individual counseling, group therapy, family therapy, dual-diagnosis care, and medication management.

Life Skills Training:

Daily schedules often incorporate practical skill-building (such as cooking, time management, and coping strategies) to prepare individuals for independent living.

Duration:

Stays commonly range from 30, 60, or 90 days to several months or longer, depending on individual recovery goals.

Who It Is For

Residential treatment is typically recommended for individuals who need more intensive care than traditional outpatient therapy can provide, such as those dealing with:

  • Severe or persistent substance use disorders
  • Complex or co-occurring mental health conditions (like depression, anxiety, or PTSD)
  • Repeated relapses or an unsafe home environment that hinders recovery
  • Serious emotional or behavioral challenges in adolescents and youth

You can learn more about how these programs operate through the American Addiction Centers Guide or review child and adolescent options via the American Academy of Child & Adolescent Psychiatry. 

Impact of Substance Use Disorder

Substance use disorder (SUD) is a treatable medical condition that alters brain function and affects physical health, mental well-being, relationships, and society.

Physical and Health Effects

Brain and Nervous System:

Changes brain chemistry, overloads the dopamine reward system, impairs judgment and impulse control, and can lead to cognitive disorders, seizures, or strokes.

Organ Damage:

Long-term use can cause chronic issues like liver disease, heart attacks or cardiomyopathy, lung disease, kidney failure, and increased cancer risks.

Dependence and Overdose:

Causes physical and psychological dependence, withdrawal symptoms (such as tremors, anxiety, and nausea), and life-threatening risks of overdose.

Infectious Diseases:

Sharing injection equipment or engaging in high-risk behaviors increases the transmission of HIV, hepatitis C, and other blood-borne infections.

Mental and Emotional Effects

Co-occurring Disorders:

Frequently worsens or triggers mental health conditions like depression, severe anxiety, and psychosis.

Spiritual and Emotional Strain:

Often leads to chronic feelings of guilt, shame, isolation, fear, and hopelessness.

Social, Relationship, and Family Effects

Interpersonal Conflict:

Causes high rates of tension, broken trust, and emotional or physical distress among family members and partners.

Family Instability:

Can result in domestic violence, separation, divorce, or child welfare involvement.

Developmental Impacts:

Prenatal exposure to substances can lead to birth defects or neonatal abstinence syndrome, while children of parents with SUD face higher risks of emotional and behavioral struggles.

Educational, Financial, and Legal Effects

Employment and School:

Frequently leads to declining academic performance, dropping out, job loss, or chronic unreliability.

Financial Hardship:

Drains personal and family resources due to the cost of substances or lost income.

Legal Consequences:

Increases the risk of arrests, driving under the influence (DUI) charges, incarceration, and involvement with the juvenile or criminal justice systems.

Learn more about symptoms and evidence-based care through the Cleveland Clinic Substance Use Disorder Guide or find treatment options via the CDC Overdose Prevention Portal.

 

If you get a DUI do you have Substance Use Disorder?

No — getting a DUI is not one of the DSM‑5 criteria for Substance Use Disorder, but it can be a consequence that signals possible underlying problematic substance use. The DSM‑5 diagnosis requires meeting at least 2 of 11 behavioral and physiological criteria, none of which include legal charges like a DUI.

Does a DUI Count as a DSM‑5 Criterion?

The DSM‑5 lists 11 specific criteria for Substance Use Disorder (SUD), such as impaired control, social impairment, risky use, tolerance, and withdrawal.

Legal problems (e.g., DUI) were part of the older DSM‑IV “substance abuse” category but were removed in DSM‑5. Therefore, a DUI alone does not meet any DSM‑5 criterion.

Why a DUI Still Matters Clinically

Even though a DUI is not a diagnostic criterion, research shows: A DUI often reflects risky use, which is a DSM‑5 criterion (continued use in physically hazardous situations). A significant proportion of people arrested for DUI meet criteria for Alcohol Use Disorder — estimates range from 35–75% across studies. About 50% of people arrested for drunk driving meet clinical criteria for Alcohol Use Disorder.

DSM‑5 Criteria Overview

Diagnosis requires meeting ≥2 of 11 criteria, including:

Bottom Line

A DUI is not a DSM‑5 criterion, but it is a red flag that often correlates with meeting other criteria for Substance Use Disorder.

 

DSM-5 criteria for substance use disorder

The 11 DSM-5 Criteria for SUD - 11 diagnostic criteria fall into four primary categories:

Impaired Control:

Taking larger amounts or using for longer than intended, unsuccessful efforts to cut down, spending excessive time obtaining or recovering from the substance, and experiencing strong cravings.

Social Impairment:

Failing to fulfill major obligations at work, school, or home, continued use despite interpersonal problems, and abandoning important social or recreational activities

Risky Use:

Repeatedly using in hazardous situations (such as driving while impaired) and continuing use despite physical or psychological harm.

Pharmacological Criteria:

Developing tolerance (needing more for the same effect or experiencing reduced effects) and experiencing withdrawal symptoms or using to relieve them.


Why and when is substance use disorder hopeless?

Addiction does not have a single, universal "survival rate" because survival depends heavily on the substance used, frequency of use, access to treatment, and other health factors. However, large-scale data show that about 75% of people who experience addiction eventually recover and go on to live full, healthy lives. 

Key Recovery and Survival Statistics

Long-Term Recovery:

Research published by the CDC and the National Institute on Drug Abuse indicates that roughly three out of four individuals with a substance use disorder achieve long-term remission or recovery over time. 

Relapse vs. Permanent Outcome:

Early relapse rates for substance use disorders range from 40% to 60%, similar to other chronic conditions like diabetes or hypertension, but the risk of relapse drops below 15% after five years of continuous sobriety. 

One-Year Recovery Rates by Substance:

Success or abstinence rates at one year vary depending on the primary substance:

Alcohol: ~41%

Amphetamines / Marijuana: ~38–40%

Prescription Opioids / Benzodiazepines: Moderate rates

Fentanyl: ~31%

Methamphetamine: ~30%

Cocaine: ~30%

Heroin: ~29% 

Mortality and Life Expectancy Impact:

Chronic substance use significantly reduces life expectancy. For instance, studies estimate that daily or heavy use of substances like heroin, methamphetamine, or cocaine can subtract anywhere from 10 to over 50 years of life depending on the frequency and age of onset. 

Overdose Trends:

U.S. drug overdose deaths have trended downward following recent public health interventions like the distribution of the reversal drug Narcan, though annual fatalities still impact tens of thousands of individuals nationwide.